Home
Products
Learn
About
Pricing
Log In
PIQ
Asset Logo

Proteomics International Laboratories Ltd

πŸ‡¦πŸ‡Ί ASX

πŸ”­ LIFE SCIENCES TOOLS & SERVICES

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

+ 0.56%
Annual Growth

5 years average annual capital growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

14
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bioanalytical services. The company specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. The company focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identified up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.

πŸ“ˆ Performance

Price History

+98.62%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.36

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in PIQ

14

πŸ“Š Total Capital Earnings

$41K

πŸ”ƒ Average investment frequency

24 weeks

πŸ’΅ Average investment amount

$2,523

⏰ Last time a customer invested in PIQ

10 days
PIQ investor breakdown
πŸ’΅ Income of investors

More than 200k

7%

150k - 200k

7%

100k - 150k

20%

50k - 100k

27%

Less than 50k

33%
πŸ‘Ά Age of investors

18 - 25

21%

26 - 34

14%

35 - 90

64%
πŸ™‹ Legal gender of investors

Female

36%

Male

64%

Pearlers who invest in PIQ also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

9.68%

πŸ“Š Share price

$102.21 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

πŸ’Έ FINANCIALS

🧱 MATERIALS

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

Find Out More

Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The company is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

πŸ™Œ Performance (5Yr p.a)

328.33%

πŸ“Š Share price

$24.47 AUD

🧬 BIOTECHNOLOGY

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. The company is headquartered in Perth, Western Australia. The Company’s operations include Mt Weld, Lynas Malaysia, Kalgoorlie and Lynas USA. The company focuses on developing the Mt Weld resource, which includes ongoing exploration, production of mixed rare earths concentrates, and an expansion project to increase concentrate feedstock production to support 12,000 tons per annum of finished NdPr oxide. The Lynas Malaysia advanced materials plant is located on a 100-hectare site in the Gebeng Industrial Estate, a purpose-built petrochemical industry zone near Kuantan, on the east coast of Malaysia. Its rare earths processing facility in Kalgoorlie undertakes value-added processing of rare earths. The firm's subsidiaries include Lynas Malaysia Sdn Bhd, Lynas Africa Ltd, Lynas Kalgoorlie Pty Ltd and Lynas USA LLC.

πŸ™Œ Performance (5Yr p.a)

66.42%

πŸ“Š Share price

$7.65 AUD

πŸ•ŠοΈ SOCIALLY AWARE

⛏️ MINING

Boss Energy Ltd. engages in the exploration of gold and uranium projects. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2007-07-25. The Honeymoon Uranium Project is located in South Australia, 80 kilometer (km) northwest of the town of Broken Hill. Its Project consists of two main exploration areas (the Eastern and Western tenement regions) with one granted Mining Lease 6109 (ML6109), totaling a 2,595 square kilometer (km2) tenement package, which covers approximately 980 km2 of pastoral leases. The project also consists of five Exploration Leases (EL) covering prospects at Honeymoon and Gould's Dam, 70 km northwest of Honeymoon. The company operates through two segments: Australian uranium operations and Alta Mesa operations. The company also operates 30%-owned Alta Mesa Project in South Texas is a high-grade uranium In-Situ Recovery (ISR) project in South Texas, a prolific United States district for sandstone-hosted ISR production, having produced approximately 80 million pounds (Mlb) historically.

πŸ™Œ Performance (5Yr p.a)

144.17%

πŸ“Š Share price

$3.94 AUD

⚑️ ENERGY

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

15.72%

πŸ“Š Share price

$135.23 AUD

🌏 GLOBAL

πŸ€– TECHNOLOGY

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

Want more shares? Try these...

PIODA

πŸ“Š Share price

$0.08 AUD
Compare
Add to watchlist